The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Daniel M. Halperin, Melissa Lynne Johnson, Jennifer A. Chan, Lowell L. Hart, Natalie Cook, Vipul M. Patel, Benjamin L. Schlechter, Judith Cave, Afshin Dowlati, Lawrence Scott Blaszkowsky, Tim Meyer, Jennifer Rachel Eads, Daniel Culp, Kristina Kriksciukaite, Laura Mei, Mark Bilodeau, Jeffrey Bloss, Matthew H. Kulke
Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, Dana-Farber Cancer Institute, Florida Cancer Specialists & Research Institute, University of Manchester, Gaston Memorial Hospital, University Hospital Southampton NHS Foundation Trust, University Hospitals Cleveland Medical Center, Case Western Reserve University, Massachusetts General Hospital, University College London, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Tarveda Therapeutics (United States), Boston Medical Center
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3169873235